• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

GoodRx Doesn't Look So Good

Here's what it's going to take to turn the charts positive.
By BRUCE KAMICH
Mar 15, 2022 | 02:22 PM EDT
Stocks quotes in this article: GDRX

Shares of GoodRx ( GDRX) have been under selling pressure since late October. The company gathers current prices and discounts to help you find the lowest cost pharmacy for your prescriptions. Sounds like everyone would want to use it but that does not mean the stock will rally. 
 
Let's check.  
 
In this daily bar chart of GDRX, below, we see a bearish picture. Prices made a small rally from July to October but then turned lower. Prices are trading below the declining 50-day moving average line and the declining 200-day line.
 
The On-Balance-Volume (OBV) line has been weak and tells us that sellers of GDRX have been more aggressive than buyers. The 12-day price momentum study has not given us any signs that the pace of the decline is slowing down. 
 
 
 
In this weekly Japanese candlestick chart of GDRX, below, we have another bearish picture. Prices are in a downtrend. No bottom reversal patterns are visible. The slope of the 40-week moving average line is negative.
 
The weekly OBV line is bearish and so is the Moving Average Convergence Divergence (MACD) oscillator as it is below the zero line. 
 
 
In this daily Point and Figure chart of GDRX, below, we can see that prices have reached and exceeded a downside price target in the $17 area. 
 
 
Bottom line strategy: It's going to take aggressive buying of the stock to turn the charts positive. Avoid the long side. 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Healthcare | Pharmaceuticals | Software & Services

More from Investing

Buying Momentum SNAPs Under Weight of Recession Worries

James "Rev Shark" DePorre
May 24, 2022 4:26 PM EDT

The Dow held its own, but under the surface it wasn't so pretty as the correction churns on.

Meta Platforms: I'm Looking at the Charts, Not the Headlines

Bruce Kamich
May 24, 2022 2:30 PM EDT

Buyers have been attracted in the $180 area in March, April and now.

Boston Scientific Could Be Wicked Good in This Kind of Market

Brad Ginesin
May 24, 2022 2:13 PM EDT

Here's why this healthcare stock is a potential port in the storm for investors.

Bettin' a Buck on Devon

Mark Sebastian
May 24, 2022 1:39 PM EDT

Here's where I see Devon Energy going and how to play it.

Can This China Tech ETF Surprise on the Upside?

Bruce Kamich
May 24, 2022 1:18 PM EDT

Sometimes the most uncomfortable trade can be the best trade.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • 10:10 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "Market Timing for Dummies"
  • 01:44 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10 Portfolio

    We're making a series of trades here.
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login